b cell lymphoma

Summary

Summary: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.

Top Publications

  1. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
  2. pmc Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
    R E Davis
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1374, USA
    J Exp Med 194:1861-74. 2001
  3. ncbi Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
    Stefano Monti
    The Broad Institute, Cambridge, MA, USA
    Blood 105:1851-61. 2005
  4. ncbi Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
    R A Clynes
    Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Ave, New York, New York 10021, USA
    Nat Med 6:443-6. 2000
  5. pmc Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases
    Ana V Miletic
    Program of Inflammatory Disease Research, Infectious and Inflammatory Disease Center, Cancer Center, Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA
    J Exp Med 207:2407-20. 2010
  6. ncbi The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    Andreas Rosenwald
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 346:1937-47. 2002
  7. ncbi Epstein-Barr virus: 40 years on
    Lawrence S Young
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TT, UK
    Nat Rev Cancer 4:757-68. 2004
  8. ncbi Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities
    Lluis Colomo
    Hematopathology Section, Laboratory of Pathology, and Department of Hematology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Surg Pathol 28:736-47. 2004
  9. pmc Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
    Andreas Rosenwald
    Metabolism Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Exp Med 198:851-62. 2003
  10. ncbi DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway
    K M Frank
    Howard Hughes Medical Institute, Boston, Massachusetts, USA
    Mol Cell 5:993-1002. 2000

Research Grants

  1. Anti-Idiotype Therapy of Human B Cell Malignancy
    Ronald Levy; Fiscal Year: 2007
  2. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
  3. Statins &Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
    Marianne Ulcickas Yood; Fiscal Year: 2013
  4. JULIE MARIE VOSE; Fiscal Year: 2016
  5. Brian Till; Fiscal Year: 2016
  6. Fnip1 Function in Lymphocyte Development, Activation and Metabolism
    Brian M Iritani; Fiscal Year: 2013
  7. Michael A Teitell; Fiscal Year: 2015
  8. Hao Wu; Fiscal Year: 2014
  9. Jack T Stapleton; Fiscal Year: 2016
  10. Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer
    John L Cleveland; Fiscal Year: 2013

Detail Information

Publications335 found, 100 shown here

  1. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    ..We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma...
  2. pmc Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
    R E Davis
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1374, USA
    J Exp Med 194:1861-74. 2001
    Gene expression profiling has revealed that diffuse large B cell lymphoma (DLBCL) consists of at least two distinct diseases. Patients with one DLBCL subtype, termed activated B cell-like (ABC) DLBCL, have a distinctly inferior prognosis...
  3. ncbi Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
    Stefano Monti
    The Broad Institute, Cambridge, MA, USA
    Blood 105:1851-61. 2005
    ..These studies identify tumor microenvironment and host inflammatory response as defining features in DLBCL and suggest rational treatment targets in specific DLBCL subsets...
  4. ncbi Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
    R A Clynes
    Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Ave, New York, New York 10021, USA
    Nat Med 6:443-6. 2000
    ....
  5. pmc Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases
    Ana V Miletic
    Program of Inflammatory Disease Research, Infectious and Inflammatory Disease Center, Cancer Center, Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA
    J Exp Med 207:2407-20. 2010
    ..This study reveals that PTEN and SHIP act cooperatively to suppress B cell lymphoma and provides the first direct evidence that SHIP is a tumor suppressor...
  6. ncbi The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    Andreas Rosenwald
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 346:1937-47. 2002
    ..The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival...
  7. ncbi Epstein-Barr virus: 40 years on
    Lawrence S Young
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TT, UK
    Nat Rev Cancer 4:757-68. 2004
    ..Despite such ubiquity, the link between EBV and 'endemic' Burkitt's lymphoma proved consistent and became the first of an unexpectedly wide range of associations discovered between this virus and tumours...
  8. ncbi Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities
    Lluis Colomo
    Hematopathology Section, Laboratory of Pathology, and Department of Hematology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Surg Pathol 28:736-47. 2004
    ..In conclusion, DLBCLs with plasmablastic differentiation are a heterogeneous group of neoplasms with different clinicopathological characteristics that may correspond to different entities...
  9. pmc Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
    Andreas Rosenwald
    Metabolism Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Exp Med 198:851-62. 2003
    Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be distinguished from other types of diffuse large B cell lymphoma (DLBCL) reliably...
  10. ncbi DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway
    K M Frank
    Howard Hughes Medical Institute, Boston, Massachusetts, USA
    Mol Cell 5:993-1002. 2000
    ....
  11. pmc Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas
    Xing Wang
    Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Proc Natl Acad Sci U S A 99:15018-23. 2002
    ..Our results not only demonstrate an important mechanism governing the expression of BCL-6, but also explain how BCL-6 is deregulated in a large number of DLBCL patients, providing a better understanding of BCL-6-related lymphomagenesis...
  12. ncbi High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma
    Fabrizio Marcucci
    Istituto Superiore di Sanita, Rome, Italy
    Haematologica 91:554-7. 2006
    ..75-7.66). HBV/HCV co-infection was found in four cases, but in no controls. The finding of a positive association between HBV infection and B-NHL raises the possibility that HBV may play an etiologic role in the induction of B-NHL...
  13. pmc 1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma
    Alexandra Fournier
    INSERM U823, Institut Albert Bonniot, Grenoble, France
    EMBO Mol Med 2:159-71. 2010
    ..By detailed investigations of a 1q12 translocation to chromosome 2p, in a case of human B cell lymphoma, aberrant aHCF were shown to be localized to the nuclear periphery and to arise as a consequence of long ..
  14. ncbi Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin
    Armando Lopez-Guillermo
    Department of Hematology, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    J Clin Oncol 23:2797-804. 2005
    ..To study the main clinicobiologic features, response, and outcome of patients with diffuse large B-cell lymphoma (DLBCL) according to the primary site, lymph node, or different extranodal organs of the disease...
  15. pmc c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells
    Murali Gururajan
    Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA
    Blood 106:1382-91. 2005
    ..Thus, JNK may act via c-Myc and Egr-1, which were shown to be important for B-lymphoma survival and growth...
  16. ncbi PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling
    Thomas T Su
    The Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Nat Immunol 3:780-6. 2002
    ..Together, these data define an essential role for PKC-beta in BCR survival signaling and highlight PKC-beta as a key therapeutic target for B-lineage malignancies...
  17. ncbi ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
    Randy D Gascoyne
    Department of Oncogeneiss and Signaling in Hematopoietic Cells, Instiut National de la Santé et de la Recherche Médicale U 563, Centre de Physiopatholgie de Toulouse Purpan, France
    Blood 102:2568-73. 2003
    ....
  18. ncbi CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model
    Kutlu G Elpek
    Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, USA
    J Immunol 178:6840-8. 2007
    ..Using the A20 B cell lymphoma as a transplantable tumor model, we demonstrate that this tumor employs multiple direct (expression of ..
  19. pmc Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
    R K Lindemann
    Cancer Immunology Program, The Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 104:8071-6. 2007
    ..Using the Emu-myc model of B cell lymphoma, we screened tumors with defined genetic alterations in apoptotic pathways for therapeutic responsiveness to ..
  20. ncbi The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy
    F Dammacco
    Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Italy
    Semin Liver Dis 20:143-57. 2000
    ..Current data indicate a higher prevalence of overt B-cell non-Hodgkin's lymphoma in HCV-infected patients, especially in some geographic areas...
  21. ncbi BAFF, APRIL and human B cell disorders
    Stuart G Tangye
    Centenary Institute of Cancer Medicine and Cell Biology, Newtown, NSW, Australia
    Semin Immunol 18:305-17. 2006
    ..It will also highlight relevant differences between the function of BAFF in humans and mice and the impact of this on the therapeutic utility of BAFF antagonists in the treatment of different human diseases...
  22. ncbi Chromosomal and gene amplification in diffuse large B-cell lymphoma
    P H Rao
    Cell Biology Program and the Departments of Pathology and Human Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 92:234-40. 1998
    ..These data show, for the first time, that amplification of chromosomal regions and genes is a frequent phenomenon in DLBL and demonstrates their potential significance in lymphomagenesis...
  23. pmc Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis
    Jodi R Alt
    Eppley Institute for Cancer Research, Department of Pathology and Microbiology, 987696 University of Nebraska Medical Center, Omaha, NE 68198, USA
    EMBO J 22:1442-50. 2003
    ..Mdm2(+/-)E micro -myc transgenics had greatly protracted rates of B cell lymphoma development with life spans twice that of wild-type transgenic littermates...
  24. ncbi Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma
    J J F Muris
    Department of Pathology, VU Medical Centre, Amsterdam, The Netherlands
    J Pathol 208:714-23. 2006
    ..Its predictive power is stronger than previously published algorithms based on only GCB/ABC- or apoptosis-regulating proteins...
  25. ncbi Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma
    Gustaaf W van Imhoff
    Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Clin Oncol 24:4135-42. 2006
    ....
  26. ncbi Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival
    Shahab Uddin
    King Fahad National Center for Children s Cancer and Research, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
    Blood 108:4178-86. 2006
    ..In multivariate analysis, this correlation was no longer significant. Altogether, these results suggest that the PI3K/AKT pathway may be a potential target for therapeutic intervention in DLBCL...
  27. pmc Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
    C M Eischen
    Department of Biochemistry, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Genes Dev 13:2658-69. 1999
    ..Therefore, Myc activation strongly selects for spontaneous inactivation of the ARF-Mdm2-p53 pathway in vivo, cancelling its protective checkpoint function and accelerating progression to malignancy...
  28. ncbi Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients
    Takashi Oyama
    Department of Hematology and Chemotherapy, Aichi Cancer Center, Nagoya, Japan
    Am J Surg Pathol 27:16-26. 2003
    ..Further investigations are needed to clarify the pathogenesis of this disease and to determine the optimal treatment strategy...
  29. ncbi Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype
    Elizabeth Crabb Breen
    Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin Immunol 109:119-29. 2003
    Interleukin-10 (IL10) may contribute to the development of non-Hodgkin's B cell lymphoma, especially in the context of acquired immunodeficiency syndrome (AIDS), where lymphoma incidence is greatly increased...
  30. ncbi Regulatory roles of altered N- and O-glycosylation of CD45 in galectin-1-induced cell death in human diffuse large B cell lymphoma
    Osamu Suzuki
    Fukushima Medical University, School of Medicine, Department of Pathology, 1 Hikarigaoka, Fukushima 960 1295, Japan
    Int J Oncol 26:1063-8. 2005
    To clarify the functions of CD45 N- and O-glycans in diffuse large B cell lymphoma (DLBCL), we analyzed the antiproliferative effects of bovine galectin-1 (beta-galactoside-binding lectin-1), which reacts with CD45 N-glycans and O-..
  31. ncbi The regulatory roles of cell surface sialylation and N-glycans in human B cell lymphoma cell adhesion to galectin-1
    Osamu Suzuki
    Department of Pathology, School of Medicine, Fukushima Medical University, Fukushima 960 1295, Japan
    Int J Oncol 28:155-60. 2006
    ..the regulatory roles of cell surface sialylation in cell adhesion to galectin-1 in the human diffuse large B cell lymphoma (DLBCL) cell line, HBL-2, and Burkitt's lymphoma cell line, HBL-8...
  32. ncbi Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma
    Murali Gururajan
    Department of Microbiology, Immunology and Molecular Genetics, Sanders Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA
    J Immunol 176:5715-9. 2006
    ..The BCR signals in lymphoma appear to be mediated by Syk, as it is constitutively active in a variety of B lymphoma cells. Blocking Syk activity by selective inhibitors suppresses growth of several murine and human B lymphomas...
  33. ncbi A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
    Michael Hummel
    Institute of Pathology, Campus Benjamin Franklin, Charite Universitatsmedizin, Berlin, Germany
    N Engl J Med 354:2419-30. 2006
    ..We used transcriptional and genomic profiling to define Burkitt's lymphoma more precisely and to distinguish subgroups in other types of mature aggressive B-cell lymphomas...
  34. ncbi Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936
    P A S Evans
    Haematological Malignancy Diagnostic Service, The General Infirmary at Leeds, Leeds, UK
    Leukemia 21:207-14. 2007
    ..Our study indicates that the BIOMED-2 multiplex PCR assays provide a powerful strategy for clonality assessment in B-cell malignancies resulting in high Ig clonality detection rates particularly when IGH and IGK strategies are combined...
  35. doi Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
    ..This randomised trial assessed whether six or eight cycles of R-CHOP-14 can improve outcome of these patients compared with six or eight cycles of CHOP-14...
  36. ncbi Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:67-74. 2002
    ..These data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted...
  37. ncbi Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Lymphoma 5:98-101. 2004
    ..These results confirm that 90Y ibritumomab tiuxetan produces high response rates and durable remissions in patients with previously treated low-grade, follicular, and transformed NHL...
  38. ncbi Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice
    Sung Sup Park
    Laboratory of Genetics, Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 65:1306-15. 2005
    ....
  39. ncbi The proto-oncogene BCL-6 in normal and malignant B cell development
    Huifeng Niu
    Institute of Cancer Genetics, University of Columbia, New York, NY 10032, USA
    Hematol Oncol 20:155-66. 2002
    ..This suggests that deregulated expression of BCL-6 may contribute to lymphomagenesis...
  40. ncbi Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice
    Tadashi Ohara
    Department of Internal Medicine, Tokyo Dental College, Chiba Hospital, Chiba 261 8502, Japan
    Anticancer Res 24:3723-30. 2004
    ..The present study was undertaken to examine the possibility and mechanism of direct induction of apoptosis of the tumor cells by the antibiotics used for bacterial eradication therapy...
  41. doi Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas
    Marc Antoine Belaud-Rotureau
    EA 2406 Histologie et Pathologie Moléculaire des Tumeurs, Universite Victor Segalen, Batiment 3B, 2eme etage, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Virchows Arch 452:607-20. 2008
    ..for Research and Treatment of Cancer has individualized three main categories among the primary cutaneous B cell lymphoma (PCBCL): leg-type primary cutaneous large B cell lymphoma (PCLBCL leg type), primary cutaneous follicle ..
  42. pmc A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas
    Leandro C Cerchietti
    Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA
    Nat Med 15:1369-76. 2009
    ..PU-H71 also induced cell death in primary human DLBCL specimens...
  43. doi The Wiskott-Aldrich syndrome protein regulates CTL cytotoxicity and is required for efficient killing of B cell lymphoma targets
    Julie De Meester
    INSERM U563, and Université Toulouse III Paul Sabatier, Purpan University Hospital, Toulouse, France
    J Leukoc Biol 88:1031-40. 2010
    ..Importantly, the use of a gene therapy lentiviral vector was sufficient to restore efficient cytotoxic activity. Our study suggests that CTL dysfunction contributes to the development of hematological malignancies in WAS patients...
  44. ncbi Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:2453-63. 2002
    ....
  45. ncbi Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype
    Bruno Petitjean
    Département de Pathologie and EA2348, Hopital Henri Mondor, AP HP, Creteil, France
    Am J Surg Pathol 26:724-32. 2002
    ..Moreover, we show that this lymphoma entity likely originates from B cells at a late stage of differentiation and occasionally shares an aberrant dual B/T phenotype...
  46. ncbi Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications
    Philipp J Jost
    III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Blood 109:2700-7. 2007
    ..In addition, we summarize recent data that validates the NF-kappaB signaling pathway as an attractive therapeutic target in T- and B-cell malignancies...
  47. pmc EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas
    Kathy H Y Shair
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS Pathog 3:e166. 2007
    ..These results suggest that Akt, NFkappaB, and Stat3 pathways may serve as effective targets in the treatment of EBV-associated B cell lymphomas...
  48. ncbi Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
    P McLaughlin
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2825-33. 1998
    ..It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies...
  49. ncbi Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma
    Susmit Suvas
    Immunology Laboratory, Institute of Microbial Technology, Postgraduate Institute of Medical Education and Research, Chandigarh 160036, India
    J Biol Chem 277:7766-75. 2002
    ..this study is the first demonstration of a distinct signaling event induced by CD80 and CD86 molecules in B cell lymphoma. Finally, the significance of the finding is that CD80 provided negative signal for the proliferation and IgG ..
  50. ncbi Molecular diagnosis of Burkitt's lymphoma
    Sandeep S Dave
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 354:2431-42. 2006
    ..We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma...
  51. ncbi A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis
    Duonan Yu
    Department of Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania, PA 19104 6051, USA
    Oncogene 21:1922-7. 2002
    ..Our model would also be instrumental in assessing the transforming potential of Myc mutants and in studying cooperation between Myc and other oncogenes...
  52. ncbi Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies
    Rhona Stein
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, 520 Belleville Ave, Belleville, NJ 07109, USA
    Blood 104:3705-11. 2004
    ....
  53. pmc The biology of human lymphoid malignancies revealed by gene expression profiling
    Louis M Staudt
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Adv Immunol 87:163-208. 2005
    ..The implications of these insights for the diagnosis and treatment of non-Hodgkin lymphomas are discussed...
  54. ncbi BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma
    Javeed Iqbal
    Leukemia Lymphoma Molecular Profiling Project, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 3135, USA
    J Clin Oncol 24:961-8. 2006
    ..DLBCL is heterogeneous, and the expression of BCL2 is variable within the two major subgroups of DLBCL, germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL, as well as primary mediastinal DLBCL...
  55. pmc NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes
    H H Lee
    Department of Microbiology and Molecular Genetics, Jonsson Comprehensive Cancer Center, and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 96:9136-41. 1999
    ..Thus, our results suggest that CD40-mediated cell survival proceeds through NF-kappaB-dependent up-regulation of Bcl-2 family members...
  56. ncbi Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line
    M Bentz
    Abteilung Innere Medizin III, Universitat Ulm, Germany
    Genes Chromosomes Cancer 30:393-401. 2001
    ..We also present a novel MBL cell line, MedB-1, which carries the genetic aberrations characteristic of this entity...
  57. ncbi Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study
    Alfonso Mele
    Istituto Superiore di Sanita, Rome La Sapienza University, Rome, Italy
    Blood 102:996-9. 2003
    ..The estimated AR was 4.6%. This study confirms an association between HCV and B-NHL. In Italy, 1 of 20 instances of B-NHL may be attributable to HCV infection and may, thus, benefit from antiviral treatment...
  58. ncbi Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
    G A Wiseman
    Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Eur J Nucl Med 27:766-77. 2000
    ..The only toxicity of note is hematologic and is not correlated to red marrow radiation absorbed dose estimates or T(1/2), reflecting that hematologic toxicity is dependent on bone marrow reserve in this heavily pretreated population...
  59. ncbi TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma
    S C Peh
    Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
    Am J Surg Pathol 25:925-9. 2001
    ..The absence in other types that may be morphologically similar indicates that staining for TARC may aid in differential diagnosis...
  60. ncbi Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection
    Olivier Hermine
    Department of Hematology and Centre National de la Recherche Scientifique Unité Mixte de Recherche 8603, Hopital Necker, Paris, France
    N Engl J Med 347:89-94. 2002
    ..We undertook this study after a patient with splenic lymphoma with villous lymphocytes had a hematologic response after antiviral treatment of HCV infection...
  61. pmc Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells
    Jonathan M Irish
    Department of Medicine, Oncology Division, Baxter Laboratory for Genetic Pharmacology, Stanford University Medical Center, Stanford, CA 94305 5151, USA
    Blood 108:3135-42. 2006
    ..BCR signaling pathways that are potentiated specifically in lymphoma cells should provide new targets for therapeutic attention...
  62. ncbi A loss-of-function RNA interference screen for molecular targets in cancer
    Vu N Ngo
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 441:106-10. 2006
    ..The methodology that we describe can be used to establish a functional taxonomy of cancer and help reveal new classes of therapeutic targets distinct from known oncogenes...
  63. ncbi A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma
    R A Messmann
    Developmental Therapeutics Program, Clinical Trials Unit, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 6:1302-13. 2000
    ..CD22 (RFB4-dgA) and CD19 (HD37-dgA; Combotox) in a Phase I trial involving 22 patients with refractory B cell lymphoma to determine the maximum tolerated dose, clinical pharmacology, and toxicity profile and to characterize any ..
  64. pmc IL-6 transgenic mouse model for extraosseous plasmacytoma
    Alexander L Kovalchuk
    Laboratory of Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:1509-14. 2002
    ..These findings provide a unique model of extramedullary PCT for studies on pathogenesis and treatment and suggest a previously unappreciated role for IL-6 in the genesis of germinal center-derived lymphomas...
  65. ncbi De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients
    Motoko Yamaguchi
    Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
    Blood 99:815-21. 2002
    ..Of particular interest is that CD5+ DLBCL was characterized by a survival curve significantly inferior to that for patients with CD5- DLBCL (P =.0026). These findings suggest that CD5+ DLBCL may constitute a unique subgroup of DLBCL...
  66. ncbi AID is required for germinal center-derived lymphomagenesis
    Laura Pasqualucci
    Institute for Cancer Genetics, the Departments of Pathology and Genetics and Development, and The Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA
    Nat Genet 40:108-12. 2008
    ..Here we have crossed three mouse models of B cell lymphoma driven by oncogenes (Myc, Bcl6 and Myc/Bcl6; refs...
  67. ncbi Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas
    L Pasqualucci
    Institute for Cancer Genetics and the Department of Pathology, Columbia University, New York, New York 10032, USA
    Nature 412:341-6. 2001
    ..By mutating multiple genes, and possibly by favouring chromosomal translocations, aberrant hypermutation may represent the major contributor to lymphomagenesis...
  68. ncbi Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification
    S A Pileri
    Chair of Pathologic Anatomy and Lymphoma Unit, L and A Seràgnoli Institute of Haematology and Clinical Oncology, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Histopathology 41:482-509. 2002
    ..The more recent acquisitions on the pathobiology of DLBCLs are reviewed in the light of the authors' experience, aiming to contribute to the existing debate on the topic...
  69. ncbi Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection
    Manuel Ramos-Casals
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, School of Medicine, University of Barcelona, Barcelona, Spain
    Arthritis Rheum 57:161-70. 2007
    To characterize the clinical and immunologic patterns of expression, response to therapy, and outcome of patients with Sjögren's syndrome (SS) and associated hepatitis C virus (HCV) infection who developed B cell lymphoma.
  70. ncbi Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
    T El Gnaoui
    Department of Clinical Hematology, Henri Mondor Hospital, Assistance Publique Hopitaux de Paris, Paris XII University, Creteil, France
    Ann Oncol 18:1363-8. 2007
    ..Rituximab, gemcitabine and oxaliplatin are active as single agents in relapsed or refractory lymphoma, and have demonstrated synergistic effects in vitro and in vivo...
  71. ncbi Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
    Margaret A Shipp
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 8:68-74. 2002
    ..Our data indicate that supervised learning classification techniques can predict outcome in DLBCL and identify rational targets for intervention...
  72. ncbi Membranoproliferative glomerulonephritis associated with low-grade B cell lymphoma presenting in the kidney
    M B Stokes
    Department of Pathology, New York University Medical Center, New York, NY 10016, USA
    Clin Nephrol 57:303-9. 2002
    Low-grade B cell lymphoma of mucosa-associated tissue type (MALToma) rarely may involve the kidney...
  73. ncbi A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy
    Clemens A Schmitt
    Cold Spring Harbor Laboratory, 1 Bungtown Road, New York 11724, USA
    Cell 109:335-46. 2002
    ..Therefore, cellular senescence contributes to treatment outcome in vivo...
  74. ncbi Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
    Lluis Colomo
    Department of Pathology, Hospital Clinic, Institut de Recerca Biomèdica August Pi i Sunyer, University of Barcelona, Spain
    Blood 101:78-84. 2003
    ..In conclusion, differentiation profile was associated with particular clinicopathological features but was not essential to predicting outcome in DLBCL patients...
  75. ncbi Anti-idiotype x anti-CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma
    Esther Avin
    Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Immunol 173:4736-43. 2004
    ..bispecific Abs with specificity to the adhesion molecule, CD44, and to an idiotypic determinant of the murine B cell lymphoma, 38C-13...
  76. ncbi Quantification of gel-separated proteins and their phosphorylation sites by LC-MS using unlabeled internal standards: analysis of phosphoprotein dynamics in a B cell lymphoma cell line
    Pedro R Cutillas
    Cell Signalling Group, Ludwig Institute for Cancer Research, 91 Riding House Street, London, W1W 7BS
    Mol Cell Proteomics 4:1038-51. 2005
    ..an internal standard to investigate the effects of pervanadate on protein phosphorylation in the WEHI-231 B cell lymphoma cell line and to assess the role of phosphoinositide 3-kinase (PI3K) in these phosphorylation events...
  77. ncbi Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Mark S Kaminski
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:7985-93. 2005
    ..To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab...
  78. ncbi Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group
    Emiko Sakane-Ishikawa
    Department of Pathology, Osaka University Graduate School of Medicine, Suita, Japan
    J Clin Oncol 23:8012-7. 2005
    ..BACH2 possesses an inhibitory effect on proliferation of Raji cell lines derived from Burkitt's lymphoma. In this study, the prognostic significance of BACH2 expression was examined in diffuse large B-cell lymphoma (DLBCL)...
  79. ncbi The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis
    Fabrice Jardin
    Département d hématologie clinique, Centre Henri Becquerel, Rouen, France
    Pathol Biol (Paris) 55:73-83. 2007
    ....
  80. ncbi MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma
    Charles H Lawrie
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Int J Cancer 121:1156-61. 2007
    Diffuse large B cell lymphoma (DLBCL) is an aggressive malignancy that accounts for nearly 40% of all lymphoid tumors...
  81. ncbi Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions
    B Bonavida
    Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Oncogene 26:3629-36. 2007
    ..Furthermore, the above findings have identified several gene products that can serve as new prognostic/diagnostic biomarkers as well as targets for therapeutic intervention in B-NHL...
  82. ncbi Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells
    P Wang
    Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Oncogene 27:1590-8. 2008
    ..Therefore, increased Mdm2 expression facilitated B-cell lymphomagenesis, in part, through regulation of p53 by altering B-cell proliferation and susceptibility to apoptosis, and by inducing chromosomal instability...
  83. pmc TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
    Roland Schmitz
    Institute of Cell Biology Cancer Research, Medical School, University of Duisburg Essen, 45122 Essen, Germany
    J Exp Med 206:981-9. 2009
    ..Extending the mutation analysis to primary mediastinal B cell lymphoma (PMBL), another lymphoma with constitutive NF-kappaB activity, revealed destructive mutations in 5 out of 14 ..
  84. pmc Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice
    E Racila
    Department of Microbiology, University of Texas Southwestern Medical Center, Dallas 75235, USA
    J Exp Med 181:1539-50. 1995
    Tumor dormancy can be induced in a murine B cell lymphoma (BCL1) by immunizing BALB/c mice with the tumor immunoglobulin (Ig) before tumor cell challenge...
  85. ncbi Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development
    Y Gao
    Howard Hughes Medical Institute, The Children s Hospital, and Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 404:897-900. 2000
    ..Our findings support a crucial role for the non-homologous end-joining pathway as a caretaker of the mammalian genome, a role required both for normal development and for suppression of tumours...
  86. ncbi Mechanisms of chromosomal translocations in B cell lymphomas
    R Kuppers
    Institute of Cancer Genetics, Columbia University, New York, NY 10032, USA
    Oncogene 20:5580-94. 2001
    ....
  87. ncbi Mediastinal (thymic) large B-cell lymphoma: where do we stand?
    Thomas F E Barth
    Department of Pathology, University of Ulm, German
    Lancet Oncol 3:229-34. 2002
    ..We review the available data on MBL with special emphasis on its morphological, immunological, and genetic properties. Also discussed are recent data on molecular genetics, biology, and treatment...
  88. ncbi Gene expression profiles of cutaneous B cell lymphoma
    Monique N Storz
    Department of Pathology, Division of Medical Oncology, Stanford University Medical Center, Stanford, California 94305, USA
    J Invest Dermatol 120:865-70. 2003
    ..Duplicate specimens clustered together demonstrating a reproducible technique. Within the cutaneous B cell lymphoma specimens two specific B cell differentiation stage signatures of germinal center B cells and plasma cells ..
  89. ncbi Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome
    I Simonitsch-Klupp
    Department of Clinical Pathology, University of Vienna, Vienna, Austria
    Leukemia 18:146-55. 2004
    ..001). Our data indicate a strong association of plasmablastic/plasmacytoid morphology with TP53 deletions, poor response to chemotherapy and short survival...
  90. ncbi High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas
    Min Sun Shin
    Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, Rockville, Maryland 20852, USA
    Cancer Res 64:4419-27. 2004
    ..The combined use of proviral tagging and analyses of gene expression thus provides a powerful approach to understanding of genes that collaborate in tumorigenesis...
  91. ncbi Mechanisms of B-cell lymphoma pathogenesis
    Ralf Kuppers
    Institute for Cell Biology Tumor Research, University of Duisburg Essen, Medical School, Germany
    Nat Rev Cancer 5:251-62. 2005
    ..Recent insights into the lymphomagenic role of factors supplied by the microenvironment also offer new therapeutic strategies...
  92. ncbi Primary peripheral B cell lymphoma, Burkitt-like, of the cranial vault
    Akiko Tanimura
    Department of Internal Medicine, Sapporoshirakabadai Hospital, Sapporo, Japan
    Acta Haematol 113:258-61. 2005
    ..medium-sized cells which were immunoreactive with CD45, CD20, CD79a, and CD10, and a diagnosis of peripheral B cell lymphoma, Burkitt-like, was made...
  93. ncbi High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers
    Feng Wang
    Department of Medical Oncology, Sun Yat sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangzhou, People s Republic of China
    Cancer 109:1360-4. 2007
    ..The authors investigated the prevalence of hepatitis B virus (HBV) infection by using serologic markers in non-Hodgkin lymphoma (NHL) compared with other types of cancers in Chinese patients...
  94. ncbi A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma
    Masumichi Saito
    Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Cancer Cell 12:280-92. 2007
    ..downregulation, while its constitutive expression caused by chromosomal translocations leads to diffuse large B cell lymphoma (DLBCL)...
  95. pmc The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma
    Trupti Joshi
    The Ohio State University Biochemistry Program, The Ohio State University, Columbus, Ohio, USA
    PLoS ONE 4:e4208. 2009
    ..To understand the regulation of macrophage-mediated ADCC, we used human B cell lymphoma coated with Rituximab as the tumor target and murine macrophages primed with IFNgamma as the effectors...
  96. ncbi Monoclonal antibody therapy of B cell lymphoma
    George J Weiner
    Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
    Expert Opin Biol Ther 4:375-85. 2004
    ..Research geared towards understanding mAb mechanisms of action and the rational design of the next generation of mAb-based regimens will allow us to take full advantage of this exciting new mode of therapy...
  97. doi Genomic profiles in B cell lymphoma
    Masao Seto
    Division of Molecular Medicine, Department of Cancer Genetics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
    Int J Hematol 92:238-45. 2010
    ..Based on these findings, the future prospect and direction of lymphoma research will be discussed...
  98. ncbi Neoplastic cells do not carry bcl2-JH rearrangements detected in a subset of primary cutaneous follicle center B-cell lymphomas
    Beatrice Vergier
    Equipe Histologie et Pathologie Moléculaire, Universite Victor Segalen, Bordeaux, France
    Am J Surg Pathol 28:748-55. 2004
    ..Our study also underlines the diagnostic value of interphase fluorescence in situ hybridization to discriminate between t(14;18)-negative PCFL and extracutaneous FL involving the skin...
  99. ncbi Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15
    S Sasaki
    Department of Pediatrics, School of Medicine, Hirosaki University, Japan
    Oncogene 19:3739-49. 2000
    ..Among 25 informative cases, five (20%) showed LOH. These results indicate that BACH2 plays important roles in regulation of B cell development...
  100. ncbi Hepatitis C virus (HCV) and lymphomagenesis
    Wen Kai Weng
    Department of Medicine, Division of Oncology, CCSR 1105a, Stanford University School of Medicine, Stanford, CA 94305, USA
    Leuk Lymphoma 44:1113-20. 2003
    ..B cell lymphoproliferative disorders, including mixed cryoglobulinemia, usually a benign condition, and overt B cell lymphoma. A direct role of HCV infection in the genesis of these B cell lymphoproliferative disorders has been ..
  101. ncbi Cyclosporine A effectively inhibits graft-versus-host disease during development of Epstein-Barr virus-infected human B cell lymphoma in SCID mouse
    Runliang Gan
    Cancer Research Institute, Medical School, Nanhua University, Hengyang 421001, China
    Cancer Sci 94:796-801. 2003
    ..Treatment with CSA had no effect on the tumor incidence in hu-PBL/SCID chimeras after active EBV infection. Accordingly, serum level of sIL-2R is a valuable indicator of GVHD occurrence in hu-PBL/SCID chimeras...

Research Grants82

  1. Anti-Idiotype Therapy of Human B Cell Malignancy
    Ronald Levy; Fiscal Year: 2007
    Abstract[unreadable] The goal of this project is to develop a new method of treatment for Human B cell lymphoma. The immunoglobulin made by each malignant B cell tumor (idiotype) is unique and has been proven to be an effective target ..
  2. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  3. Statins &Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
    Marianne Ulcickas Yood; Fiscal Year: 2013
    ..e., diffuse large B cell lymphoma)...
  4. JULIE MARIE VOSE; Fiscal Year: 2016
    ..The BMT/CTN including our consortium will be the only clinical cooperative group to accomplish this goal. ..
  5. Brian Till; Fiscal Year: 2016
    ..caspase 9 safety switch will be expanded and infused into patients with relapsed or refractory aggressive B cell lymphoma following autologous stem cell transplantation...
  6. Fnip1 Function in Lymphocyte Development, Activation and Metabolism
    Brian M Iritani; Fiscal Year: 2013
    ..Remarkably, loss of Fnip1 also protects against pre-B cell lymphoma induced by c-Myc in a mouse model of Burkitt's B cell lymphoma...
  7. Michael A Teitell; Fiscal Year: 2015
    ..Defects in this pathway were identified in pilot studies of human B cell lymphoma samples by ATM or LKB1 repression or by a recently identified somatic mutation or genetic polymorphism in ..
  8. Hao Wu; Fiscal Year: 2014
    ..These translocations likely activate NF-kB through MALT1 and Bcl10 overexpression. Collectively, these studies suggest that the CBM complex is an attractive therapeutic target neoplastic disorders of the lymphocytes. ..
  9. Jack T Stapleton; Fiscal Year: 2016
    ..As a secondary analysis, the association of GBV-C with NHL subtypes (diffuse large B cell lymphoma, other B-cell lymphomas, follicular lymphoma, or T cell lymphomas) will be examined, although power to assess ..
  10. Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer
    John L Cleveland; Fiscal Year: 2013
    ..Using validated Myc-driven mouse models of B cell lymphoma and mammary adenocarcinoma, and of K-Ras-directed lung adenocarcinoma, we will test the roles of Odc in ..
  11. In Vivo Imaging of bcl-2 Expression in Lymphoma
    Michael R Lewis; Fiscal Year: 2012
    ..5% of its victims are U.S. war veterans. The goal of the proposed research is central to the VHA mission of providing primary and specialized care to cancer patients who are veterans. ..
  12. Gregory J Gores; Fiscal Year: 2016
    ..The results of these studies are germane to mechanisms of liver injury in the common syndrome of nonalcoholic fatty liver disease, and have the potential to identify new therapeutic strategies for this liver disease. ..
  13. Grant McFadden; Fiscal Year: 2014
    ..We will explore the functional significance of these host cell signaling activations for the successful ex vivo tumor cell purging of human leukemia calls by MV. ..
  14. Michael A Teitell; Fiscal Year: 2015
    ..periods we showed that the TCL1 proto-oncogene was abnormally expressed in samples from three major GC B cell lymphoma categories, including follicular (FL), Burkitt (BL), and diffuse large B cell (DLBCL) lymphomas...
  15. Damian J Green; Fiscal Year: 2014
    ..This project is designed to develop a new approach, already proven effective for patients with leukemia and lymphoma, that directly targets multiple myeloma cells with small radioactive particles to selectively destroy them. ..
  16. Vitamin D and Non-Hodgkin Lymphoma Prognosis
    Jennifer L Kelly; Fiscal Year: 2012
    ..on improved prognosis in colorectal cancer, multiple myeloma, breast cancer, and most recently diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), two of the most prevalent non-Hodgkin lymphoma (NHL) subtypes...
  17. MARKUS MUSCHEN; Fiscal Year: 2016
    ..The proposed discrimination between Type I and Type II ALL resembles the classification of mature B cell lymphoma, in which subgroups can be distinguished based on the presence (i.e...
  18. miRNA HD Array Platform
    Bruce E Seligmann; Fiscal Year: 2010
    ..and a training set of archived formalin fixed paraffin embedded biopsies from patients with diffuse large B cell lymphoma (DLBCL), who subsequently received chemotherapy plus anti-CD20 monoclonal Ritixan, will be tested...
  19. Sophia S Wang; Fiscal Year: 2016
    ..Public health relevance: successful completion of this study will contribute to the understanding of host genetic variation and tumor markers in NHL survival. ..
  20. MOLECULAR PATHOGENESIS OF HYPERPARATHYROIDISM
    Andrew Arnold; Fiscal Year: 2012
    ....
  21. Sherie L Morrison; Fiscal Year: 2015
    ..murine or human IFNa exhibited potent anti-tumor effects against a human CD20+ murine lymphoma and human B cell lymphoma both in vitro and in vivo...
  22. Kelly L Gorres; Fiscal Year: 2014
    ..In addition, these mechanistic studies on SCFAs and HDAC inhibitors may help to explain the connection between diet and carcinogenesis and provide clues to how SCFAs can be applied for clinical use. ..
  23. Development of cambinol analogues as antilymphoma agents
    Antonio Bedalov; Fiscal Year: 2012
    ..Our goal is to use the tools of medicinal chemistry, protein crystallography, biochemistry and cell biology to develop potent and selective inhibitors of SIRT1 as anti-lymphoma drugs. ..
  24. Immune-pathophysiology of lymphocytic foci in Sjogren's syndrome
    Cuong Q Nguyen; Fiscal Year: 2010
    ..Although SjS is generally not considered a lethal disease in the absence of B cell lymphoma formation, patients have an increasingly diminished quality of life with disease progression...
  25. 1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
    Jerry D Glickson; Fiscal Year: 2012
    ..Here we are developing much more sensitive 1H NMR methods that can be used for early detection of response in all NHL patients. The same methods should be applicable to other prevalent forms of human cancer. ..
  26. Regulation of Immunity and Inflammation by TIPE2
    Youhai H Chen; Fiscal Year: 2013
    ..by blocking the functions of the activation receptor-induced signalosome (ARIS) that contains Bcl10 (B cell lymphoma 10), MALT1 (mucosa-associated lymphoid tissue lymphoma translocation gene 1), IKK (Inhibitor of NF-?B kinase) ..
  27. Molecular Mechanisms of Myelokathexis
    Andrew Aprikyan; Fiscal Year: 2009
    ..We will study the efficacy of this drug and its analogs in the cellular and animal models of this disease prior to initiating clinical trials in patients. ..
  28. TRANSCRIPTIONAL REPRESSION AND ACTIVATION BY YY1
    Yang Shi; Fiscal Year: 2010
    ..Abnormal B cell proliferation and differentiation are the main causes for B cell lymphoma and leukemia...
  29. B Cell Expressed COX2 and AID Dependent Sjogrens Syndrome Autoimmunity
    PATRICIA K MONGINI; Fiscal Year: 2013
    ..gland inflammation, AID-expressing B cells, pathogenic IgG autoAbs that impair salivation, and a high rate of B cell lymphoma. Furthermore, stimuli linked to SjS in humans and/or mouse models are known to be inducers of B cell COX-2 ..
  30. CD20-targeted IL-15 immunotherapeutic for B-cell malignancies
    Hing C Wong; Fiscal Year: 2012
    ....
  31. Motor protein regulation of T cell receptor signaling
    Joel L Pomerantz; Fiscal Year: 2012
    ..GAKIN associates with CARD11 in a region in which oncogenic mutations have been found in Diffuse Large B cell Lymphoma (DLBCL)...
  32. IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
    Genhong Cheng; Fiscal Year: 2012
    ....
  33. Biological consequences of a lymphoma-associated mutation in Ezh2 in mice
    Ann J Feeney; Fiscal Year: 2013
    ..high frequency in one specific subtype of cancer: the germinal center (GC) B cell subtype of diffuse large B cell lymphoma (GCB-DLBCL)...
  34. Functions of Bcl10 in Lymphocytes
    Renren Wen; Fiscal Year: 2009
    ..abstract_text> ..
  35. Molecular Basis of Action of the Putative Oncogene BCL-6
    Vivian J Bardwell; Fiscal Year: 2012
    ..Thus proteins of the BCOR complex provide candidate therapeutic targets for treatment of B cell lymphoma. We also have found that BCOR is a common insertion site in retrovirally-induced B cell lymphomas, and that ..
  36. Targeting B-cell lymphoma with Leukothera
    Benjamin A Belinka; Fiscal Year: 2013
    ..The data that we generate from the work described in this application is necessary to provide proof-of-principle and mechanistic knowledge for subsequent clinical testing in lymphoma patients. ..
  37. Origin of CD5+ B cell Lymphoma/Leukemia in Mice
    Kyoko Hayakawa; Fiscal Year: 2013
    ..This system allows a detailed investigation of lymphoma developmental potential in tissues from early to late stage leukemogenesis, a study not possible in humans. ..
  38. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ....
  39. ILLANA ALLAKE STANLEY; Fiscal Year: 2014
    ..In addition this study may reveal useful insights into the molecular underpinnings of metabolic heterogeneity in other types of cancer. ..
  40. NF-KB and mTOR regulation in Waldenstrom Macroglobulinemia
    Irene M Ghobrial; Fiscal Year: 2013
    ....
  41. Roles for Human PARPs in Regulating the Cytoskeleton and Cell Motility
    MELISSA CHESARONE CATALDO; Fiscal Year: 2012
    ....
  42. Brenda M Birmann; Fiscal Year: 2015
    ....
  43. RICARDO C AGUIAR; Fiscal Year: 2016
    ..Finally, as the potential of inhibiting and restoring miRNA levels with therapeutic intent is becoming a reality, our studies may provide a blueprint for testing this concept in cancer. ..
  44. Prognostic Markers for HIV-Postive Diffuse Large B-Cell Lymphoma
    Chun R Chao; Fiscal Year: 2011
    ..Our results may also help to identify new molecular therapeutic targets for resistant tumor and assist with the building of an outcome prediction equation for risk-stratified patient management. ..
  45. Deep Sequencing of Small Regulatory RNAs in Diffuse Large B cell Lymphoma
    Changchun Xiao; Fiscal Year: 2010
    ..to take advantage of recent advances in deep sequencing technology and a unique collection of diffuse large B cell lymphoma (DLBCL) consortium cases to address the following challenge: to develop a comprehensive knowledge of small ..
  46. HTS to Identify Novel Chemical Probes for CCR6
    GREGORY PAUL ROTH; Fiscal Year: 2010
    ..We show supporting preliminary data validating the role of CCR6 in B cell lymphoma and metastasis and provide a plan for an assay platform suitable for high throughput screening...
  47. Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2
    CICELY ANNE JETTE; Fiscal Year: 2010
    ..The goal of this application is to use the zebrafish model system to identify targets for small molecule inhibitors of Bcl-2 function in order to restore normal cell death pathways in cancer cells. ..
  48. CHRISTOPHER JANMIN CHENG; Fiscal Year: 2014
    ..This proposal seeks to further dissect this phenomenon in order to provide insights into miRNA and cancer biology, as well as establish a new paradigm for miRNA-targeted cancer therapy. ..
  49. Alcohol Consumption and Risk of NHL: Role of MTOR Dysfunction
    Ronald B Gartenhaus; Fiscal Year: 2013
    ..abstract_text> ..
  50. Interplay of Myc, Tumor Supressors and Regulators of Differentiation in Lymphoma
    John L Cleveland; Fiscal Year: 2012
    ..studies supported by CA076379- 11A1, using the validated E[unreadable]-Myc transgenic mouse model of human B cell lymphoma, have demonstrated that Myc-mediated activation of the Arf-p53 tumor suppressor pathway, and its selective ..
  51. Systems Biology of Tumor Progression and Drug-Resistance
    Andrea Califano; Fiscal Year: 2010
    ..and experimental models, including (a) Progression from Follicular Lymphoma (FL) to Diffuse Large B Cell Lymphoma (DLBCL) (b) Glucocorticoid resistance in T-lineage Acute Lymphoblastic Leukemia (T-ALL), and (c) the ..
  52. Ari M Melnick; Fiscal Year: 2014
    ....
  53. David Wang; Fiscal Year: 2015
    ..It is likely that other cancers have an infectious etiology and identifying new associations would have a significant impact on early diagnosis, treatment, and prevention of cancer. ..
  54. Differential Signaling by B cell Receptor in Tolerance Induction
    Haochu Huang; Fiscal Year: 2012
    ..is technically challenging to carry out shRNA screen in vivo, we will first carry out the screen on WEHI-231 B cell lymphoma cell line...
  55. Comparative Mechanisms of Genomic Instability
    Karen M Vasquez; Fiscal Year: 2010
    ..These discoveries should begin to unravel the pathogenesis of diseases that are caused by genomic instability, and ultimately to the development of new approaches for treatment and prevention. ..
  56. Role of miR155 in Leukemogenesis
    Carlo M Croce; Fiscal Year: 2012
    ..is overexpressed in aggressive CLLs, in a fraction of Burkitt's lymphomas, in ABC type of diffuse large B cell lymphoma and in several solid tumors...
  57. Role of Polycomb-mediated epigenetic regulation in diffuse large B cell lymphoma
    Ann J Feeney; Fiscal Year: 2013
    ..high frequency in one specific subtype of cancer: the germinal center (GC) B cell subtype of diffuse large B cell lymphoma (GCB-DLBCL)...
  58. Detection of Light Chain Restriction in non-Hodgkin Lymphoma by a Novel RNA In Si
    Xiao Jun Ma; Fiscal Year: 2012
    ..many non-Hodgkin lymphoma (NHL), including the most common NHL variants - follicular lymphoma, diffuse large B cell lymphoma, small B lymphocytic lymphoma, and extranodal marginal zone lymphoma of MALT type...
  59. EASTERN COOPERATIVE ONCOLOGY GROUP
    THOMAS MATTHEW HABERMANN; Fiscal Year: 2013
    ..Biologic observations are predicting outcomes and moving to new therapeutic approaches in patients with outcomes as predicted by their presenting biology. ..
  60. Mechanisms of subtelomere recombination in telomerase deficient tumors
    Tammy A Morrish; Fiscal Year: 2012
    ..Thus we intend to examine whether non-LTR retrotransposons also contribute to telomere maintenance in both human and mouse cells and thus account for the occurrence of tumors lacking telomerase. ..
  61. Steven Horwitz; Fiscal Year: 2015
    ....
  62. Tammy A Morrish; Fiscal Year: 2015
    ..Thus we intend to examine whether non-LTR retrotransposons also contribute to telomere maintenance in both human and mouse cells and thus account for the occurrence of tumors lacking telomerase. ..
  63. The role and functional mechanism of a miRNA cluster, mir-17-92 in leukemogenesis
    Jianjun Chen; Fiscal Year: 2012
    ....
  64. JOHN ALAN DIEHL; Fiscal Year: 2016
    ....
  65. SEVENTEENTH INTERNATIONAL HERPESVIRUS WORKSHOP
    S Hayward; Fiscal Year: 1992
    ....
  66. Molecular Epidemiology of non-Hodgkin Lymphoma Survival
    James R Cerhan; Fiscal Year: 2010
    ..Host genetics may also lead to a better understanding of NHL pathophysiology that could lead to new approaches to improve the survival of NHL patients. ..
  67. MOLECULAR EPIDEMIOLOGY OF AIDS-ASSOCIATED LYMPHOMA
    Otoniel Martinez Maza; Fiscal Year: 2004
    DESCRIPTION (Provided by the applicant): Non-Hodgkin' s B cell lymphoma (AIDS-lymphoma) is seen in greatly-elevated frequency in HIV-infected people, not only in North America and Europe, but worldwide...
  68. Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
    Sattva S Neelapu; Fiscal Year: 2010
    ....
  69. Overcoming tumor cell resistance to apoptosis with a natural product, GCS-100
    Linda G Baum; Fiscal Year: 2010
    ..Galectin-3 is highly overexpressed in a specific type of lymphoma, termed diffuse large B cell lymphoma (DLBCL) and promotes apoptosis resistance in DLBCL cells...
  70. BC1-2 REARRANGEMENTS IN CLL
    Louise Showe; Fiscal Year: 1992
    ..The (14;18) chromosome translocation has also been shown to be associated with some cases of diffuse B cell lymphoma which do not show a history of previous follicular lymphoma...
  71. ARSENIC TRIOXIDE TREATMENT OF LYMPHOPROLIFERATIVE DISORD
    Samuel Waxman; Fiscal Year: 2003
    ..Should our laboratory study identify agents or schedules that enhance the response to As203, we will use them to appropriately modify the initial phase II pilot study. ..
  72. A Highly Multiplexed PCR Platform for Gene Expression Profiling from FFPE Tissue
    JORK N NOLLING; Fiscal Year: 2012
    ....
  73. Anti-CTLA-4 Monoclonal Antibody Therapy for Lymphoma
    John Timmerman; Fiscal Year: 2005
    ..Given the unique susceptibility of B cell lymphoma to immunotherapeutic interventions, we hypothesize that anti-CTLA-4 should have significant clinical activity ..
  74. RADIOIMMUNOTHERAPY OF B CELL LYMPHOMA WITH ANTI CD74
    M Mattes; Fiscal Year: 2002
    ..Preliminary data shows effective therapy of systemic B cell lymphoma in SCID mice by 111In-LL1...
  75. THERAPEUTIC DNA VACCINES TO TREAT B CELL LYMPHOMA
    Peter Hobart; Fiscal Year: 2000
    ..Developments in DNA technologies, such as robotic cloning and characterization of genes, will make commercial development of patient- specific vaccines feasible. ..
  76. REGULATION OF POLYPLOIDY BY CYTIDYLYLTRANSFERASE (CT)
    Zheng Cui; Fiscal Year: 2002
    ..Deficiency of CT can activate the overexpressed B cell lymphoma gene 2 protein (Bcl-2p) to induce the formation of stable and viable tetraploid cells from diplod cells...
  77. BACTERIAL EXPRESSION OF LYMPHOMA RNRNASE IMMUNOTOXIN
    SHUI ON LEUNG; Fiscal Year: 1999
    ..The fusion protein can be used for the treatment of B-cell lymphoma. ..